

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The effect of tart cherry juice on risk of gout attacks: protocol for a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-035108
Article Type:	Protocol
Date Submitted by the Author:	22-Oct-2019
Complete List of Authors:	Lamb, Kirstie; Sheffield Hallam University Sheffield Business School, Food and Nutrition Group Lynn, Anthony; Sheffield Hallam University Sheffield Business School, Food and Nutrition Russell, Jean; The University of Sheffield, Corporate Information and Computing Services Barker, Margo; Sheffield Hallam University Sheffield Business School, Food and Nutrition
Keywords:	RHEUMATOLOGY, GOUT, TART CHERRY, NUTRITION & DIETETICS, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Protocol (BMJ Open)

The effect of tart cherry juice on risk of gout attacks: protocol for a randomised controlled trial

16 Kirstie Lamb^{1*}, Anthony Lynn¹, Jean Russell² and Margo E Barker¹

17
18
19
20 ¹Food and Nutrition Group, Sheffield Business School, Sheffield Hallam University, Sheffield, UK

21
22 ²Corporate Information and Computing, University of Sheffield, Sheffield, UK

23
24
25
26 *Correspondence to kirstie.lamb@student.shu.ac.uk; Sheffield Business School, Stoddard Building,
27 Sheffield Hallam University, City Campus, Howard Street, S1 1WB
28
29

30
31 Word Count (excluding title page, abstract, references, figures and tables): 2880
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Gout is a painful form of inflammatory arthritis associated with several comorbidities, particularly cardiovascular disease. Cherries, which are rich in anti-inflammatory and anti-oxidative bioactive compounds, are proposed to be efficacious in preventing and treating gout, but recommendations to patients are conflicting. Cherry consumption has been demonstrated to lower serum urate levels and inflammation in several small studies. One observational case-crossover study reported that cherry consumption was associated with reduced risk of recurrent gout attacks. This preliminary evidence requires substantiation. The proposed randomised clinical trial aims to test the effect of consumption of tart cherry juice on risk of gout attacks.

Methods and analysis: This 12-month, parallel, double-blind, randomised, placebo-controlled trial will recruit 120 individuals (aged 18-80 years) with a confirmed diagnosis of gout and who have experienced a flare in the last year. Participants will be randomly assigned to an intervention group, which will receive Montmorency tart cherry juice daily for a 12-m period, or a corresponding placebo group, which will receive a cherry-flavoured placebo drink. The primary study outcome is change in frequency and intensity of self-reported gout attacks. Secondary outcome measures include serum urate concentration, fractional excretion of uric acid, biomarkers of inflammation, blood lipids and other markers of cardiovascular risk. Other secondary outcome measures will be changes in physical activity and functional status. Statistical analysis will be conducted on an intention-to-treat basis.

Ethics and dissemination: This study has been granted ethical approval by the National Research Ethics Service, Yorkshire and The Humber - Leeds West Research Ethics Committee (ref: 18/SW/0262). Results of the trial will be submitted for publication in a peer-reviewed journal.

Trial registration number: NCT03621215.

Strengths and limitations of this study

- This study will be the first randomised, double-blind, placebo-controlled trial to examine the effectiveness of tart cherry juice to reduce risk of recurrent gout flares.
- Primary and secondary outcomes are central to treatment of gout and its co-morbidities.
- This study will investigate mechanisms whereby tart cherry juice may reduce risk of recurrent gout flares and co-morbidities.
- The study design addresses the temporal risk of gout flares by assessing patients over a 12-month period and retention of participants may be challenging.

INTRODUCTION

Gout is a debilitating and common type of inflammatory arthritis exerting a significant health burden.[1,2] The proportion of people afflicted with gout in the UK is substantial; around 3% of adults were affected in 2012, representing approximately 1.9 million people.[3] Men are typically at greater risk of developing gout than women and risk increases with age for both genders.[3] Gout is associated with numerous co-morbidities, including cardiovascular disease (CVD), obesity and hypertension.[3–5]

Acute recurrent attacks of arthritis are a defining feature of gout.[6] The underlying cause is a build-up of monosodium urate crystalline deposits in the joints, particularly those of the lower limbs causing acute pain, redness and inflammation.[7,8] Gout attacks are intermittent and may last from several days to up to several weeks. Usually only one joint is affected. Sustained hyperuricaemia, which most commonly occurs secondary to reduced fractional uric acid clearance, is recognised as the most important risk factor for gout.[9,10] Consumption of purine- or fructose-rich food and drink, including seafood, red meat, beer and sugar-sweetened beverages have been associated with increased uric acid levels and risk of gout flares.[11–16]

Early case reports from the 1950s suggested that consumption of cherries had a role to play in alleviating gouty pain and inflammation.[17] More recently cherries and cherry products have been shown to acutely lower serum urate after consumption in healthy people, while a daily supplement of cherry juice was associated with lower serum urate in a placebo-controlled crossover study of overweight and obese men and women.[18–20] It is unclear which bioactive component in cherries may be responsible for the effect; Bell et al proposed that anthocyanins and/or other phenolic compounds present in cherry may be important.[18]

There are very few studies in gout patients. In a case-crossover study of 633 gout sufferers, cherry consumption was associated with a 35% lower risk of gout flares.[21] This study was predicated on an acute temporal relationship between cherry consumption and likelihood of gout flares and did not evaluate the habitual effect of cherry consumption. Furthermore being observational in design, causality cannot be assumed.[21] While there have been two intervention studies that have addressed the potential for cherry to reduce risk of gout, these were both feasibility studies with limited sample size, lack of an appropriate placebo and within-group statistical comparison.[22,23]

1
2
3
4
5 In addition to lowering serum urate, cherry consumption may be of benefit in gout
6 prophylaxis because cherries contain a variety of polyphenolic compounds with anti-
7 inflammatory properties. These compounds may ameliorate the inflammatory response
8 induced by monosodium urate crystals.[18,21] Indeed, cherry consumption has been shown
9 to lower a recognised biomarker of inflammation C-reactive protein (CRP) in both healthy
10 [18,24–26] and arthritic people.[27,28]
11
12
13
14
15
16

17 Despite the limited scientific evidence base, leading medical societies and charities (for
18 example, British Society for Rheumatology, European League against Rheumatism, National
19 Institute for Clinical Excellence, Arthritis Research UK, Mayo Clinic, UK Gout Society)
20 endorse cherry consumption as a therapeutic aid for gout.[1,29–33] Contrastingly, the Food
21 and Drug Administration in the United States has warned cherry juice growers and processors
22 against making preventive disease claims.[34] A content analysis of US and UK newspapers
23 reported that 25% of articles discussing dietary management of gout advised cherry
24 consumption.[35] Notably, the UK's National Health Service health information website
25 dismissed newspaper claims that advocated cherry consumption for gout.[36] There is a clear
26 need for definitive evidence from a randomised controlled trial.
27
28
29
30
31
32
33
34
35

36 The proposed study is a 12-month RCT designed to provide superior evidence as to whether
37 tart cherries are a useful adjuvant therapy for treatment of gout. The study will also elucidate
38 possible mechanisms of effect through the measurement of serum urate, fractional urinary
39 urate excretion, biomarkers of inflammation and oxidative stress. As participants are likely to
40 be at increased risk of CVD, secondary study outcomes will be measures of arterial stiffness
41 and blood lipids.
42
43
44
45
46
47

48 **AIM AND OBJECTIVES**

49 The aim of this study is to evaluate the effects of a daily intervention of tart cherry juice over
50 a 12-month period compared with a placebo drink on risk of gout attacks.
51
52

53 The primary objective of this trial is to assess if a daily supplement of tart cherry juice
54 influences the frequency and intensity of gout attacks relative to a daily supplement of a
55 placebo drink.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Its secondary objectives are to:

- assess if tart cherry juice supplementation impacts on risk factors for cardiovascular disease
- identify the effects of tart cherry juice supplementation on putative biological mediators of risk of gout

Hypotheses

- In patients diagnosed with gout, a dietary intervention of a daily tart cherry concentrate drink for a 12-m period will reduce the frequency and intensity of gout flares compared with a placebo drink.
- In patients diagnosed with gout, a dietary intervention of a daily tart cherry concentrate drink for a 12-m period will lower markers of cardiovascular risk (arterial stiffness, blood pressure and blood lipids) compared with a placebo drink.

METHODS AND ANALYSIS

Described according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines.[37]

Study design and setting

The study is a 12-month, double-blind, two-armed, parallel RCT performed in adults aged 18 to 80 years, with an existing clinical diagnosis of gout and who have experienced at least one gout flare in the last 12 months. The intervention group will receive a daily supplement of tart cherry juice and the placebo group will receive a cherry-flavoured drink. The primary outcome measure will be between-group difference in the frequency and intensity of gout flares. Secondary outcome measures will be between-group differences in serum urate concentration, fractional excretion of uric acid, blood lipids and recognised markers of inflammation (CRP, interleukin-6, tumour necrosis factor alpha), oxidative stress and vascular function (blood pressure, arterial stiffness). Changes in physical activity, perceived health and pain will also be secondary outcomes. Non-efficacy outcomes will include dietary intake measures, for example total energy, total sugars and consumption of gout trigger foods. Each participant will be enrolled for a 12-month dietary intervention period; physical and vascular measurements and fasted blood and 24-hour urine samples collected at 0, 6 and 12 months. These measurements will be made at Sheffield Hallam University's Food and Nutrition Research Laboratories in Sheffield, United Kingdom. An overview of the study

1
2
3 design and timeline is given in Figure 1. The study opened recruitment in June 2019 and is
4 ongoing.
5
6

7 **Participants and recruitment**

9 Participants will mainly be recruited from primary care practices in the English city of
10 Sheffield and surrounding areas. The Clinical Research Network of Yorkshire and Humber,
11 which provides localised infrastructure to support delivery of research, will select practices to
12 act as Participant Identification Centres (PICs). At each PIC, computerised patient records
13 will be searched to identify eligible individuals that have a diagnosis of gout. A general
14 practitioner will screen the list of patients generated from this search for suitability to
15 participate (for example, people who are frail or suffer from dementia would not be
16 recruited). People who are eligible will be sent an invitation to participate; interested
17 individuals will be encouraged to contact the research team for further study information.
18 Such participants will be invited to attend an information, screening and enrolment meeting at
19 Sheffield Hallam University. Written informed consent will be obtained from those willing
20 to take part by the study coordinator (KL).
21
22
23
24
25
26
27
28
29
30

31 Recruitment from PICs will be augmented by poster advertising at local primary care
32 practices and across the university campus, advertising on the UK Gout Society website and
33 at local large-scale workplaces. Participants' general practitioner will be contacted to verify
34 their eligibility.
35
36
37
38

39 **Inclusion criteria**

- 40 • Aged between 18 and 80 years.
- 41 • Clinical diagnosis of gout.
- 42 • Have experienced at least one gout flare in the past 12 months.
- 43 • Participant is able to give informed consent.

44 **Exclusion criteria**

- 45 • Allergy to cherries.
- 46 • Habitual consumption of cherries and/or cherry products.
- 47 • Severe renal impairment (glomerular filtration rate <30 mg/L).
- 48 • Type 1 or type 2 diabetes.
- 49 • Recruiting practitioner deems that the patient is unsuitable to participate.

Dietary Intervention

Participants will be provided monthly with either Montmorency tart cherry concentrate (King Orchards, Michigan, USA) or a low-phenol, cherry-flavoured placebo concentrate. Both drinks will be diluted with water before consumption (30 mL of concentrate with 220 mL of water). Participants will be advised to consume their drink with breakfast and to keep the concentrate refrigerated. Consumption will be recorded daily on a calendar. Advice will be given to maintain usual dietary habits throughout the course of the intervention and to avoid cherry consumption.

Each daily serving of tart cherry has been estimated to provide: 80 kcal, 20 g carbohydrate, 870 mg phenolics and 14 mg of anthocyanins. Each serving of the placebo drink will provide: 2.9 kcal, 0.3 g carbohydrate, 13 mg phenolics and 0.2 mg anthocyanins. The placebo drink has been constituted to have similar colour and flavour as the cherry drink. It was not possible to match the drinks for energy content because the addition of sugars to the placebo drink would have jeopardised its shelf life. Furthermore, the addition of sucrose (comprising 50% fructose) has the potential to raise serum urate.[38]

Data collection

Laboratory visit data

Anthropometric measurements

Anthropometric measures of height and weight will be used to calculate Body Mass Index (weight (kg)/height (m)²). Height without shoes will be measured to the nearest 0.1 cm using a stadiometer (Seca, Hamburg, Germany). Weight will be measured in light clothing to the nearest 0.1 kg using calibrated weighing scales (Seca 899, Hamburg, Germany).

Fasting blood sample

Fasted venous blood samples will be collected. These will be analysed for: serum inflammatory markers (CRP, IL-6 and TNF- α), serum urate and blood lipids (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triacylglycerol). Oxidative DNA damage and antioxidant status will also be measured in lymphocytes using the Comet assay (single cell electrophoresis).

Urine samples

Prior to each visit, participants will carry out a 24-hour urine collection. These samples will be used to calculate 24-hour urinary uric acid excretion. A further spot urine sample will be collected alongside the fasting blood sample to calculate fractional excretion of uric acid.

Arterial stiffness

A Vicorder™ device (SMT Medical, Germany) will be used to measure brachial BP, central BP, carotid-femoral pulse wave velocity and augmentation index.

Medication use and functional status

Medication use (contemporary and historical) will be recorded. Assessment of functional status covering pain, interference with daily activities and perceived health will be collected through interview using questions from a validated scale.[39]

Self-reported data

Gout flare frequency and intensity

A gout flare diary will be completed by participants over the intervention period to assess gout flares. Participants will record detail of all flares, including duration, location, pain severity (0-10 numerical rating scale) and any medication used to treat the flare.

Assessment of diet and physical activity levels

Participants will complete a 4-day food diary using estimated household measures, and record physical activity in a diary over a 4-d period in the week preceding each laboratory visit.

Compliance

A daily calendar will be completed to record adherence to the intervention. Used drinks bottles will be collected at 6 and 12 months to further assess compliance. Routine telephone contact will be used to encourage compliance.

Retention

Participants may withdraw from the study at any time without giving any reason. Reasons for discontinuing the study will be recorded. Participants who decide to discontinue the intervention will be invited to return for follow-up visits to assess outcome measures.

Adverse events (AEs)

All AEs will be recorded and reported, where applicable, following Good Clinical Practice and Health Research Authority guidelines. Participants will be advised to report all serious or

1
2
3 non-serious AEs to the research team; these data will be recorded. Additionally, the incidence
4 of adverse events will be logged at laboratory visits and via telephone contact.
5
6

7 **Data management**

8 The collection and storage of data will adhere to the standard requirements of the EU General
9 Data Protection Regulation 2016/679. Data will be entered onto electronic spreadsheets,
10 which will be stored on a secure University server. All data will be treated confidentially and
11 anonymised for evaluation. Hard copies of data and documents will be kept in a locked and
12 secure cabinet for the duration of the study. Following completion of the study, data will be
13 transferred to Sheffield Hallam University's Research Data Archive (SHURDA), where it
14 will be kept for 10 years. Hard copies will be disposed of confidentially and electronic data
15 deleted after this period of time.
16
17
18
19
20
21
22
23

24 **Randomisation, allocation and blinding**

25 All consenting participants will be block randomised (block size 4) in a 1:1 allocation to
26 either a tart cherry juice group or a placebo cherry-flavoured drink group with stratification
27 by sex and smoking status. Allocation sequence will be generated using a computer random
28 number generator by an investigator not involved in participant enrolment and data collection
29 (AL) and concealed from research personnel until the completion of the trial. The study
30 coordinator (KL) who will be responsible for participant enrolment, distribution of
31 intervention drinks and data collection will be blinded to treatment allocation until results
32 have been analysed. Drinks will be provided to participants in identical bottles and labelled
33 with participant identification number only to ensure that both study coordinator and
34 participants are blinded to drink allocation throughout the study.
35
36
37
38
39
40
41
42
43

44 **Sample size**

45 The power calculation was based on the potential impact of tart cherry supplementation on
46 the primary outcome measure. Using data on gout occurrence in UK patients, the chance of a
47 recurrence of at least one gout flare over a 12-month period is 11%.[40] It is predicted that
48 cherry juice treatment will reduce this recurrence to one quarter of the rate of the actual
49 recurrence (from 11% to 2.7%). Based on these data, it is estimated that 94 participants
50 would provide 95% power at a significance level of 0.05. A sample of 120 participants will
51 allow for an attrition rate of approximately 20%.
52
53
54
55
56
57
58
59
60

Statistical analysis

Continuous variables will be presented as mean and confidence intervals. Statistical significance will be set at $p < 0.05$. Descriptive analysis of all baseline variables will be conducted to compare the two groups. All analyses will be performed using intention-to-treat analysis; all randomised participants will be included in the final analysis as far as data collected will allow. Independent generalised mixed model analyses of variance will be performed to test for changes in frequency of flares per month between treatments (cherry *versus* placebo); baseline, 6 months and 12 months times will be used for secondary outcomes. Analysis will be performed using IBM SPSS Statistics for Windows (New York, USA).

Patient and public involvement

Gout patients were not directly involved in development of the research question or study design. We consulted with retired people from a local church group (Christ Church Fulwood, Sheffield, England) as to their understanding of written participant information and questionnaires. This group also provided feedback on the acceptability of the schedule of visits, study measures and intervention.

Ethics and dissemination

The trial has been approved by Leeds West NHS Research Ethics Committee (18/SW/0262) and the HRA and Health and Care Research Wales (HCRW). It is registered at ClinicalTrials.gov (NCT03621215). Any protocol modifications will be sent for review by the research ethics committee and will be amended at the trial registry. Participants will be sent a summary of the trial findings when all data have been analysed. Dissemination of the study findings of this study will be through publication in a leading peer-reviewed journal and presentation at national and international conferences.

Author affiliations

¹Food and Nutrition Group, Sheffield Business School, Sheffield Hallam University, Sheffield, UK

²Corporate Information and Computing, University of Sheffield, Sheffield, UK

Acknowledgements

We acknowledge the input of Dr Tim Tait, Consultant Rheumatologist, United Lincolnshire Hospitals NHS Trust, Lincoln, England for his guidance about clinical aspects of the study protocol. We are grateful to Dr Caroline Mitchell and Dr Helen Twohig from the Academic Unit of Primary Medical Care, University of Sheffield for their helpful advice.

Contributors

AL and MEB designed the study and secured the funding. KL prepared study documents and coordinated the HRA and ethics applications. MEB and TL are joint principal investigators. KL is the study coordinator and co-investigator. KL drafted the manuscript for publication, with input from TL, JMR and MEB. JMR advised on the study design, power calculation and statistical analysis.

Funding

The sponsor of this research is Sheffield Hallam University, UK. This work is supported by the Cherry Marketing Institute (CMI), Michigan, US. CMI did not have any input into the design of the study or writing of this manuscript and will not play any role in the collection, analysis and interpretation of data. The protocol was initiated and designed by the investigators who have no personal financial relationships with CMI.

Patient recruitment to the study is supported by Yorkshire and Humber National Institute for Health Research CRN.

Competing interests

The authors declare that they have no competing interests.

Ethics approval

The study protocol (version 2.0, January 2019) was reviewed and approved by Yorkshire and The Humber Leeds West REC (Ref: 18/SW/0262).

Provenance and peer review

Not commissioned; externally peer reviewed.

Open Access

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

Figure 1. Participant flow through the study. PA; physical activity

REFERENCES

- 1 Hui M, Carr A, Cameron S, *et al.* The British Society for Rheumatology Guideline for the Management of Gout. *Rheumatology* 2017;**56**:1–20.
doi:10.1093/rheumatology/kex156
- 2 Kuo C-F, Grainge MJ, Zhang W, *et al.* Global epidemiology of gout: prevalence, incidence and risk factors. *Nat Rev Rheumatol* 2015;**11**:649–62.
doi:10.1038/nrrheum.2015.91
- 3 Kuo CF, Grainge MJ, Mallen C, *et al.* Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study. *Ann Rheum Dis* 2015;**74**:661–7. doi:10.1136/annrheumdis-2013-204463
- 4 Stack AG, Hanley A, Casserly LF, *et al.* Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. *QJM* 2013;**106**:647–58.
doi:10.1093/qjmed/hct083
- 5 Kuo C-F, Grainge MJ, Mallen C, *et al.* Comorbidities in patients with gout prior to and following diagnosis: case-control study. *Ann Rheum Dis* 2016;**75**:210–7.
doi:10.1136/annrheumdis-2014-206410
- 6 Roddy E, Doherty M. Epidemiology of gout. *Arthritis Res Ther* 2010;**12**:1–11.
doi:10.1186/ar3199
- 7 Dalbeth N, Merriman TR, Stamp LK. Gout. *Lancet* 2016;**388**:2039–52.
doi:10.1016/S0140-6736(16)00346-9
- 8 Roddy E. Revisiting the pathogenesis of podagra: Why does gout target the foot? *J Foot Ankle Res* 2011;**4**:1–6. doi:10.1186/1757-1146-4-13
- 9 Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. *Arthritis Res Ther* 2006;**8**:1–9. doi:10.1186/ar1909
- 10 Abhishek A, Doherty M. Education and non-pharmacological approaches for gout. *Rheumatology* 2018;**57**:51–8. doi:10.1093/rheumatology/kex421
- 11 Choi HK, Atkinson K, Karlson EW, *et al.* Alcohol intake and risk of incident gout in men: A prospective study. *Lancet* 2004;**363**:1277–81. doi:10.1016/S0140-

- 6736(04)16000-5
- 12 Choi JW, Ford ES, Gao X, *et al.* Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The third National Health and Nutrition Examination Survey. *Arthritis Rheum* 2008;**59**:109–16. doi:10.1002/art.23245
 - 13 Major TJ, Topless RK, Dalbeth N, *et al.* Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. *Br Med J Open* 2018;**363**:1–10. doi:10.1136/bmj.k3951
 - 14 Wang M, Jiang X, Wu W, *et al.* A meta-analysis of alcohol consumption and the risk of gout. *Clin Rheumatol* 2013;**32**:1641–8. doi:10.1007/s10067-013-2319-y
 - 15 Wang DD, Sievenpiper JL, de Souza RJ, *et al.* The effects of fructose intake on serum uric acid vary among controlled dietary trials. *J Nutr* 2012;**142**:916–23. doi:10.3945/jn.111.151951
 - 16 White SJ, Carran EL, Reynolds AN, *et al.* The effects of apples and apple juice on acute plasma uric acid concentration: a randomized controlled trial. *Am J Clin Nutr* 2018;**107**:165–72. doi:10.1093/ajcn/nqx059
 - 17 Blau LW. Cherry diet control for gout and arthritis. *Tex Rep Biol Med* 1950;**8**:309–11.
 - 18 Bell PG, Gaze DC, Davison GW, *et al.* Montmorency tart cherry (*Prunus cerasus* L.) concentrate lowers uric acid, independent of plasma cyanidin-3-O-glucosiderutinoside. *J Funct Foods* 2014;**11**:82–90. doi:10.1016/j.jff.2014.09.004
 - 19 Jacob RA, Spinozzi GM, Simon VA, *et al.* Consumption of cherries lowers plasma urate in healthy women. *J Nutr* 2003;**133**:1826–9. doi:10.1093/jn/133.6.1826
 - 20 Martin KR, Coles KM. Consumption of 100% tart cherry juice reduces serum urate in overweight and obese adults. *Curr Dev Nutr* 2019;**3**:1–9. doi:10.1093/cdn/nzz011
 - 21 Zhang Y, Neogi T, Chen C, *et al.* Cherry consumption and decreased risk of recurrent gout attacks. *Arthritis Rheum* 2012;**64**:4004–11. doi:10.1002/art.34677
 - 22 Schlesinger N, Rabinowitz R, Schlesinger M. Pilot studies of cherry juice concentrate for gout flare prophylaxis. *J Arthritis* 2012;**1**:1–5. doi:10.4172/2167-7921.1000101
 - 23 Singh JA, Green C, Morgan S, *et al.* A randomized internet-based pilot feasibility and

- 1
2
3 planning study of cherry extract and diet modification in gout. *J Clin*
4 *Rheumatol*;:Published Online First: 23 January 2019.
5 doi:10.1097/RHU.0000000000001004
6
7
8
9 24 Kelley DS, Rasooly R, Jacob RA, *et al*. Consumption of Bing sweet cherries lowers
10 circulating concentrations of inflammation markers in healthy men and women. *J Nutr*
11 2006;**136**:981–6. doi:10.1093/jn/136.4.981
12
13
14
15 25 Kelley DS, Adkins Y, Reddy A, *et al*. Sweet Bing cherries lower circulating
16 concentrations of markers for chronic inflammatory diseases in healthy humans. *J Nutr*
17 2013;**143**:340–4. doi:10.3945/jn.112.171371.the
18
19
20
21 26 Chai S, Davis K, Zhang Z, *et al*. Effects of tart cherry juice on biomarkers of
22 inflammation and oxidative stress in older adults. *Nutrients* 2019;**11**:228.
23 doi:10.3390/nu11020228
24
25
26
27 27 Kuehl KS, Elliot DL, Sleigh AE, *et al*. Efficacy of tart cherry juice to reduce
28 inflammation biomarkers among women with inflammatory osteoarthritis (OA). *J*
29 *Food Stud* 2012;**1**:14–25. doi:10.5296/jfs.v1i1.1927
30
31
32
33 28 Schumacher HR, Pullman-Mooar S, Gupta SR, *et al*. Randomized double-blind
34 crossover study of the efficacy of a tart cherry juice blend in treatment of osteoarthritis
35 (OA) of the knee. *Osteoarthr Cartil* 2013;**21**:1035–41. doi:10.1016/j.joca.2013.05.009
36
37
38
39 29 NICE. Clinical Knowledge Summary: Gout.
40 2018.<https://cks.nice.org.uk/gout#!scenario:1> (accessed 5 Sep 2019).
41
42
43
44 30 Richette P, Doherty M, Pascual E, *et al*. 2016 updated EULAR evidence-based
45 recommendations for the management of gout. *Ann Rheum Dis* 2017;**76**:29–42.
46 doi:10.1136/annrheumdis-2016-209707
47
48
49
50 31 Arthritis Research UK. Gout. 2016.[https://www.versusarthritis.org/about-](https://www.versusarthritis.org/about-arthritis/conditions/gout/)
51 [arthritis/conditions/gout/](https://www.versusarthritis.org/about-arthritis/conditions/gout/) (accessed 6 Jun 2019).
52
53
54 32 Mayo Clinic. Gout: Diagnosis and treatment.
55 2019.[https://www.mayoclinic.org/diseases-conditions/gout/diagnosis-treatment/drc-](https://www.mayoclinic.org/diseases-conditions/gout/diagnosis-treatment/drc-20372903)
56 [20372903](https://www.mayoclinic.org/diseases-conditions/gout/diagnosis-treatment/drc-20372903) (accessed 4 Jun 2019).
57
58
59
60 33 UK Gout Society. All about gout and diet.

- 1
2
3 <http://www.ukgoutsociety.org/PDFs/goutsociety-allaboutgoutanddiet-0917.pdf>
4
5 (accessed 9 Feb 2019).
6
7
8 34 U.S. Food and Drug Administration. List of firms receiving warning letters regarding
9 cherry and other fruit-based products with disease claims in labeling.
10
11 2005.[http://wayback.archive-](http://wayback.archive-it.org/7993/20170406024549/https://www.fda.gov/Food/ComplianceEnforcement/War)
12 [it.org/7993/20170406024549/https://www.fda.gov/Food/ComplianceEnforcement/War](https://www.fda.gov/Food/ComplianceEnforcement/War)
13 [ningLetters/ucm081724.htm](https://www.fda.gov/Food/ComplianceEnforcement/War) (accessed 5 May 2019).
14
15
16
17 35 Duyck SD, Petrie KJ, Dalbeth N. ‘You don’t have to be a drinker to get gout, but it
18 helps’: a content analysis of the depiction of gout in popular newspapers. *Arthritis*
19 *Care Res* 2016;**68**:1721–5. doi:10.1002/acr.22879
20
21
22
23 36 NHS Choices. Cherry juice touted as treatment for gout.
24 2014.[https://www.nhs.uk/news/food-and-diet/cherry-juice-touted-as-treatment-for-](https://www.nhs.uk/news/food-and-diet/cherry-juice-touted-as-treatment-for-gout/)
25 [gout/](https://www.nhs.uk/news/food-and-diet/cherry-juice-touted-as-treatment-for-gout/) (accessed 17 Jun 2018).
26
27
28
29 37 Chan A, Tetzlaff JM, Altman DG, *et al.* SPIRIT 2013 statement: Defining standard
30 protocol items for clinical trials. *Ann Intern Med* 2013;**158**:200–7.
31
32
33 38 Caliceti C, Calabria D, Roda A, *et al.* Fructose intake, serum uric acid, and
34 cardiometabolic disorders: A critical review. *Nutrients* 2017;**9**:395.
35 doi:10.3390/nu9040395
36
37
38
39 39 Álvarez-Hernández E, Peláez-Ballestas I, Vázquez-Mellado J, *et al.* Validation of the
40 Health Assessment Questionnaire Disability Index in patients with gout. *Arthritis*
41 *Rheum* 2008;**59**:665–9. doi:10.1002/art.23575
42
43
44
45 40 Rothenbacher D, Primatesta P, Ferreira A, *et al.* Frequency and risk factors of gout
46 flares in a large population-based cohort of incident gout. *Rheumatology* 2011;**50**:973–
47 81. doi:10.1093/rheumatology/keq363
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Participant flow through the study. PA; physical activity

209x104mm (300 x 300 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	n/a
Protocol version	#3	Date and version identifier	11
Funding	#4	Sources and types of financial, material, and other support	10-11
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1, 10

1	Roles and	#5b	Name and contact information for the trial sponsor	10
2	responsibilities:			
3	sponsor contact			
4	information			
5				
6				
7				
8	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	10-11
9	responsibilities:		collection, management, analysis, and interpretation of	
10	sponsor and funder		data; writing of the report; and the decision to submit the	
11			report for publication, including whether they will have	
12			ultimate authority over any of these activities	
13				
14				
15				
16	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	n/a
17	responsibilities:		centre, steering committee, endpoint adjudication	
18	committees		committee, data management team, and other individuals	
19			or groups overseeing the trial, if applicable (see Item 21a	
20			for data monitoring committee)	
21				
22				
23				
24	Introduction			
25				
26				
27	Background and	#6a	Description of research question and justification for	3
28	rationale		undertaking the trial, including summary of relevant	
29			studies (published and unpublished) examining benefits	
30			and harms for each intervention	
31				
32				
33				
34	Background and	#6b	Explanation for choice of comparators	7
35	rationale: choice of			
36	comparators			
37				
38				
39	Objectives	#7	Specific objectives or hypotheses	4-5
40				
41	Trial design	#8	Description of trial design including type of trial (eg,	5
42			parallel group, crossover, factorial, single group),	
43			allocation ratio, and framework (eg, superiority,	
44			equivalence, non-inferiority, exploratory)	
45				
46				
47				
48	Methods:			
49	Participants,			
50	interventions, and			
51	outcomes			
52				
53				
54				
55	Study setting	#9	Description of study settings (eg, community clinic,	5
56			academic hospital) and list of countries where data will be	
57			collected. Reference to where list of study sites can be	
58				
59				
60				

obtained

1			
2			
3	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
4			
5			
6			
7			
8			
9	Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
10			
11			
12			
13			
14	Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)
15			
16			
17			
18			
19			
20			
21	Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)
22			
23			
24			
25			
26			
27	Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
28			
29			
30			
31	Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42	Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
43			
44			
45			
46			
47			
48			
49	Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
50			
51			
52			
53			
54			
55	Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size
56			
57			
58			
59			
60			

1 **Methods:**

2 **Assignment of**
3 **interventions (for**
4 **controlled trials)**
5
6

7			
8	Allocation: sequence	#16a	Method of generating the allocation sequence (eg, 9
9	generation		computer-generated random numbers), and list of any
10			factors for stratification. To reduce predictability of a
11			random sequence, details of any planned restriction (eg,
12			blocking) should be provided in a separate document that
13			is unavailable to those who enrol participants or assign
14			interventions
15			
16			
17			
18			
19	Allocation	#16b	Mechanism of implementing the allocation sequence (eg, 9
20	concealment		central telephone; sequentially numbered, opaque, sealed
21	mechanism		envelopes), describing any steps to conceal the sequence
22			until interventions are assigned
23			
24			
25			
26	Allocation:	#16c	Who will generate the allocation sequence, who will enrol 9
27	implementation		participants, and who will assign participants to
28			interventions
29			
30			
31	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, 9
32			trial participants, care providers, outcome assessors, data
33			analysts), and how
34			
35			
36			
37	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is
38	emergency unblinding		permissible, and procedure for revealing a participant's
39			allocated intervention during the trial
40			
41			

42 **Methods: Data**
43 **collection,**
44 **management, and**
45 **analysis**
46
47

48			
49	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, 7-8
50			and other trial data, including any related processes to
51			promote data quality (eg, duplicate measurements,
52			training of assessors) and a description of study
53			instruments (eg, questionnaires, laboratory tests) along
54			with their reliability and validity, if known. Reference to
55			where data collection forms can be found, if not in the
56			
57			
58			
59			
60			

protocol

1			
2			
3	Data collection plan:	#18b	Plans to promote participant retention and complete
4	retention		follow-up, including list of any outcome data to be
5			collected for participants who discontinue or deviate from
6			intervention protocols
7			
8			
9	Data management	#19	Plans for data entry, coding, security, and storage,
10			including any related processes to promote data quality
11			(eg, double data entry; range checks for data values).
12			Reference to where details of data management
13			procedures can be found, if not in the protocol
14			
15			
16			
17	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary
18			outcomes. Reference to where other details of the
19			statistical analysis plan can be found, if not in the protocol
20			
21			
22			
23	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and
24	analyses		adjusted analyses)
25			
26			
27	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-
28	population and		adherence (eg, as randomised analysis), and any
29	missing data		statistical methods to handle missing data (eg, multiple
30			imputation)
31			
32			
33	Methods: Monitoring		
34			
35			
36	Data monitoring:	#21a	Composition of data monitoring committee (DMC);
37	formal committee		summary of its role and reporting structure; statement of
38			whether it is independent from the sponsor and competing
39			interests; and reference to where further details about its
40			charter can be found, if not in the protocol. Alternatively,
41			an explanation of why a DMC is not needed
42			
43			
44			
45			
46	Data monitoring:	#21b	Description of any interim analyses and stopping
47	interim analysis		guidelines, including who will have access to these interim
48			results and make the final decision to terminate the trial
49			
50			
51	Harms	#22	Plans for collecting, assessing, reporting, and managing
52			solicited and spontaneously reported adverse events and
53			other unintended effects of trial interventions or trial
54			conduct
55			
56			
57			
58	Auditing	#23	Frequency and procedures for auditing trial conduct, if
59			n/a
60			

any, and whether the process will be independent from investigators and the sponsor

Ethics and dissemination

Research ethics approval	#24	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	10
Protocol amendments	#25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	10
Consent or assent	#26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	6
Consent or assent: ancillary studies	#26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
Confidentiality	#27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	8-9
Declaration of interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	11
Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	11
Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	10
Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of	n/a

1 authorship professional writers
 2
 3 Dissemination policy: [#31c](#) Plans, if any, for granting public access to the full protocol, n/a
 4 reproducible research participant-level dataset, and statistical code
 5

6 Appendices

8 Informed consent [#32](#) Model consent form and other related documentation n/a
 9 materials given to participants and authorised surrogates
 10
 11

12 Biological specimens [#33](#) Plans for collection, laboratory evaluation, and storage of n/a
 13 biological specimens for genetic or molecular analysis in
 14 the current trial and for future use in ancillary studies, if
 15 applicable
 16
 17
 18

19 None The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution
 20 License CC-BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a
 21 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

The effect of tart cherry juice on risk of gout attacks: protocol for a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-035108.R1
Article Type:	Protocol
Date Submitted by the Author:	06-Jan-2020
Complete List of Authors:	Lamb, Kirstie; Sheffield Hallam University Sheffield Business School, Food and Nutrition Group Lynn, Anthony; Sheffield Hallam University Sheffield Business School, Food and Nutrition Group Russell, Jean; The University of Sheffield, Corporate Information and Computing Services Barker, Margo; Sheffield Hallam University Sheffield Business School, Food and Nutrition Group
Primary Subject Heading:	Rheumatology
Secondary Subject Heading:	Nutrition and metabolism
Keywords:	RHEUMATOLOGY, GOUT, TART CHERRY, NUTRITION & DIETETICS, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Protocol (BMJ Open)

The effect of tart cherry juice on risk of gout attacks: protocol for a randomised controlled trial

16 Kirstie Lamb^{1*}, Anthony Lynn¹, Jean Russell² and Margo E Barker¹

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

¹Food and Nutrition Group, Sheffield Business School, Sheffield Hallam University, Sheffield, UK

²Corporate Information and Computing, University of Sheffield, Sheffield, UK

*Correspondence to kirstie.lamb@student.shu.ac.uk; Sheffield Business School, Stoddard Building, Sheffield Hallam University, City Campus, Howard Street, S1 1WB

Word Count (excluding title page, abstract, references, figures and tables): 3078

ABSTRACT

Introduction: Gout is a painful form of inflammatory arthritis associated with several comorbidities, particularly cardiovascular disease. Cherries, which are rich in anti-inflammatory and anti-oxidative bioactive compounds, are proposed to be efficacious in preventing and treating gout, but recommendations to patients are conflicting. Cherry consumption has been demonstrated to lower serum urate levels and inflammation in several small studies. One observational case-crossover study reported that cherry consumption was associated with reduced risk of recurrent gout attacks. This preliminary evidence requires substantiation. The proposed randomised clinical trial aims to test the effect of consumption of tart cherry juice on risk of gout attacks.

Methods and analysis: This 12-month, parallel, double-blind, randomised, placebo-controlled trial will recruit 120 individuals (aged 18-80 years) with a clinical diagnosis of gout who have self-reported a gout flare in the previous year. Participants will be randomly assigned to an intervention group, which will receive Montmorency tart cherry juice daily for a 12-m period, or a corresponding placebo group, which will receive a cherry-flavoured placebo drink. The primary study outcome is change in frequency of self-reported gout attacks. Secondary outcome measures include attack intensity, serum urate concentration, fractional excretion of uric acid, biomarkers of inflammation, blood lipids and other markers of cardiovascular risk. Other secondary outcome measures will be changes in physical activity and functional status. Statistical analysis will be conducted on an intention-to-treat basis.

Ethics and dissemination: This study has been granted ethical approval by the National Research Ethics Service, Yorkshire and The Humber - Leeds West Research Ethics Committee (ref: 18/SW/0262). Results of the trial will be submitted for publication in a peer-reviewed journal.

Trial registration number: NCT03621215.

Strengths and limitations of this study

- This study will be the first randomised, double-blind, placebo-controlled trial to examine the effectiveness of tart cherry juice to reduce risk of recurrent gout flares.
- Primary and secondary outcomes are central to treatment of gout and its co-morbidities.
- This study will investigate mechanisms whereby tart cherry juice may reduce risk of recurrent gout flares and co-morbidities.
- The study design addresses the temporal risk of gout flares by assessing patients over a 12-month period and retention of participants may be challenging.

INTRODUCTION

Gout is a debilitating and common type of inflammatory arthritis exerting a significant health burden.[1,2] The proportion of people afflicted with gout in the UK is substantial; around 3% of adults were affected in 2012, representing approximately 1.9 million people.[3] Men are typically at greater risk of developing gout than women and risk increases with age for both genders.[3] Gout is associated with numerous co-morbidities, including cardiovascular disease (CVD), obesity and hypertension.[3–5]

Acute recurrent attacks of arthritis, also known as flares, are a defining feature of gout.[6] The underlying cause is a build-up of monosodium urate crystalline deposits in the joints, particularly those of the lower limbs causing acute pain, redness and inflammation.[7,8] Gout attacks are intermittent and may last from several days to up to several weeks. Usually only one joint is affected. Sustained hyperuricaemia, which most commonly occurs secondary to reduced fractional uric acid clearance, is recognised as the most important risk factor for gout.[9,10] Consumption of purine- or fructose-rich food and drink, including seafood, red meat, beer and sugar-sweetened beverages have been associated with increased uric acid levels and risk of gout flares.[11–16]

Early case reports from the 1950s suggested that consumption of cherries had a role to play in alleviating gouty pain and inflammation.[17] More recently cherries and cherry products have been shown to acutely lower serum urate after consumption in healthy people, while a daily supplement of cherry juice was associated with lower serum urate in a placebo-controlled crossover study of overweight and obese men and women.[18–20] It is unclear which bioactive component in cherries may be responsible for the effect; Bell et al proposed that anthocyanins and/or other phenolic compounds present in cherry may be important.[18]

There are very few studies in gout patients. In a case-crossover study of 633 gout sufferers, cherry consumption was associated with a 35% lower risk of gout flares.[21] This study was predicated on an acute temporal relationship between cherry consumption and likelihood of gout flares and did not evaluate the habitual effect of cherry consumption. Furthermore being observational in design, causality cannot be assumed.[21] While there have been two intervention studies that have addressed the potential for cherry to reduce risk of gout, these were both feasibility studies with limited sample size, lack of an appropriate placebo and within-group statistical comparison.[22,23]

1
2
3
4
5 In addition to lowering serum urate, cherry consumption may be of benefit in gout prophylaxis
6 because cherries contain a variety of polyphenolic compounds with anti-inflammatory
7 properties. These compounds may ameliorate the inflammatory response induced by
8 monosodium urate crystals.[18,21] Indeed, cherry consumption has been shown to lower a
9 recognised biomarker of inflammation C-reactive protein (CRP) in both healthy [18,24–26]
10 and arthritic people.[27,28]
11
12
13
14
15
16

17 Despite the limited scientific evidence base, leading medical societies and charities (for
18 example, British Society for Rheumatology, European League against Rheumatism, National
19 Institute for Clinical Excellence, Arthritis Research UK, Mayo Clinic, UK Gout Society)
20 endorse cherry consumption as a therapeutic aid for gout.[1,29–33] Contrastingly, the Food
21 and Drug Administration in the United States has warned cherry juice growers and processors
22 against making preventive disease claims.[34] A content analysis of US and UK newspapers
23 reported that 25% of articles discussing dietary management of gout advised cherry
24 consumption.[35] Notably, the UK's National Health Service health information website
25 dismissed newspaper claims that advocated cherry consumption for gout.[36] There is a clear
26 need for definitive evidence from a randomised controlled trial.
27
28
29
30
31
32
33
34
35

36 The proposed study is a 12-month RCT designed to provide superior evidence as to whether
37 tart cherries are a useful adjuvant therapy for treatment of gout. The study will also elucidate
38 possible mechanisms of effect through the measurement of serum urate, fractional urinary urate
39 excretion, biomarkers of inflammation and oxidative stress. As participants are likely to be at
40 increased risk of CVD, secondary study outcomes will be measures of arterial stiffness and
41 blood lipids.
42
43
44
45
46
47

48 **AIM AND OBJECTIVES**

49 The aim of this study is to evaluate the effects of a daily intervention of tart cherry juice over
50 a 12-month period compared with a placebo drink on risk of gout attacks.
51
52

53 The primary objective of this trial is to assess if a daily supplement of tart cherry juice
54 influences the frequency of gout attacks over 12 months relative to a daily supplement of a
55 placebo drink.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Its secondary objectives are to:

- assess if tart cherry juice supplementation impacts on risk factors for cardiovascular disease
- identify the effects of tart cherry juice supplementation on putative biological mediators of risk of gout

Hypotheses

- In patients diagnosed with gout, a dietary intervention of a daily tart cherry concentrate drink for a 12-m period will reduce the frequency of gout flares compared with a placebo drink.
- In patients diagnosed with gout, a dietary intervention of a daily tart cherry concentrate drink for a 12-m period will lower markers of cardiovascular risk (arterial stiffness, blood pressure and blood lipids) compared with a placebo drink.

METHODS AND ANALYSIS

Described according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines.[37]

Study design and setting

The study is a 12-month, double-blind, two-armed, parallel RCT performed in adults aged 18 to 80 years, with an existing clinical diagnosis of gout and who have reported at least one gout flare in the last 12 months. The intervention group will receive a daily supplement of tart cherry juice and the placebo group will receive a cherry-flavoured drink. The primary outcome measure will be between-group difference in the frequency of gout flares from baseline to 12 months. Secondary outcome measures will be between-group differences in gout flare pain, serum urate concentration, fractional excretion of uric acid, blood lipids and recognised markers of inflammation (CRP, interleukin-6, tumour necrosis factor alpha), oxidative stress and vascular function (blood pressure, arterial stiffness). Changes in physical activity, perceived health and pain will also be secondary outcomes. Non-efficacy outcomes will include dietary intake measures, for example total energy, total sugars and consumption of gout trigger foods. Each participant will be enrolled onto the study for 12 months; physical and vascular measurements and fasted blood and 24-hour urine samples collected at 0, 6 and 12 months. These measurements will be made at Sheffield Hallam University's Food and Nutrition Research Laboratories in Sheffield, United Kingdom. Laboratory visits will be postponed for any participant that is experiencing a gout flare until after the flare has resolved. An overview

1
2
3 of the study design and timeline is given in Figure 1. The study opened recruitment in June
4 2019 and is ongoing.
5
6

7 **Participants and recruitment**

8
9 Participants will mainly be recruited from primary care practices in the English city of Sheffield
10 and surrounding areas. The Clinical Research Network of Yorkshire and Humber, which
11 provides localised infrastructure to support delivery of research, will select practices to act as
12 Participant Identification Centres (PICs). At each PIC, computerised patient records will be
13 searched to identify eligible individuals that have a clinical diagnosis of gout. Diagnosis is
14 typically based on clinical examination, assessment of reported symptoms and elevated serum
15 urate. A general practitioner will screen the list of patients generated from this search for
16 suitability to participate (for example, people who are frail or suffer from dementia would not
17 be recruited). People who are eligible will be sent an invitation to participate; interested
18 individuals will be encouraged to contact the research team for further study information. Such
19 participants will be invited to attend an information, screening and enrolment meeting at
20 Sheffield Hallam University. Written informed consent will be obtained from those willing to
21 take part by the study coordinator (KL).
22
23
24
25
26
27
28
29
30
31
32

33 Recruitment from PICs will be augmented by poster advertising at local primary care practices
34 and across the university campus, advertising on the UK Gout Society website and at local
35 large-scale workplaces. Participants' general practitioner will be contacted to verify their
36 eligibility.
37
38
39
40

41 **Inclusion criteria**

- 42 • Aged between 18 and 80 years.
- 43 • Clinical diagnosis of gout.
- 44 • At least one self-reported gout flare with a pain score >3 (on a 0-10 numerical rating
45 scale) in the past 12 months.
- 46 • Participant is able to give informed consent.
47
48
49
50

51 **Exclusion criteria**

- 52 • Allergy to cherries.
- 53 • Habitual consumption of cherries and/or cherry products.
- 54 • Severe renal impairment (glomerular filtration rate <30 mg/L).
- 55 • Type 1 or type 2 diabetes.
56
57
58
59
60

- Recruiting practitioner deems that the patient is unsuitable to participate (frailty, dementia and terminal medical conditions).

Dietary Intervention

Participants will be provided monthly with either Montmorency tart cherry 68 Brix concentrate (King Orchards, Michigan, USA) or a low-phenol, cherry-flavoured placebo concentrate. Both drinks will be diluted with water by participants before consumption (30 mL of concentrate with 220 mL of water, totalling 250 ml daily). Graduated cups with clear markings indicating required volumes of concentrate and water will be provided to participants. Participants will be advised to consume their drink with breakfast and to keep the concentrate refrigerated. Consumption will be recorded daily on a calendar. Advice will be given to maintain usual dietary habits throughout the course of the intervention and to avoid cherry consumption.

Each daily serving of tart cherry has been estimated to provide: 80 kcal, 20 g carbohydrate, 870 mg phenolics and 14 mg of anthocyanins. Each serving of the placebo drink will provide: 2.9 kcal, 0.3 g carbohydrate, 13 mg phenolics and 0.2 mg anthocyanins. The placebo drink has been constituted to have similar colour, taste and tartness as the cherry concentrate through the addition of blue and red food colourings, red and black cherry flavourings and citric acid to a low-fruit cordial (summer fruits flavour). It was not possible to match the drinks for energy content because the addition of sugars to the placebo drink would have jeopardised its shelf life. Furthermore, the addition of sucrose (comprising 50% fructose) has the potential to raise serum urate.[38]

Data collection

Laboratory visit data

Anthropometric measurements

Anthropometric measures of height and weight will be used to calculate Body Mass Index (weight (kg)/height (m)²). Height without shoes will be measured to the nearest 0.1 cm using a stadiometer (Seca, Hamburg, Germany). Weight will be measured in light clothing to the nearest 0.1 kg using calibrated weighing scales (Seca 899, Hamburg, Germany).

Fasting blood sample

Fasted venous blood samples will be collected. These will be analysed for: serum inflammatory markers (CRP, IL-6 and TNF- α), serum urate and blood lipids (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triacylglycerol). Oxidative

1
2
3 DNA damage and antioxidant status will also be measured in lymphocytes using the Comet
4 assay (single cell electrophoresis).
5
6

7 *Urine samples*

8 Prior to each visit, participants will carry out a 24-hour urine collection. These samples will be
9 used to calculate 24-hour urinary uric acid excretion. A further spot urine sample will be
10 collected alongside the fasting blood sample to calculate fractional excretion of uric acid.
11
12
13

14 *Arterial stiffness*

15 A Vicorder™ device (SMT Medical, Germany) will be used to measure brachial BP, central
16 BP, carotid-femoral pulse wave velocity and augmentation index.
17
18
19

20 *Medication use and functional status*

21 Medication use (contemporary and historical) will be recorded at baseline and monitored
22 closely throughout the study. This record includes both prescribed and over-the-counter
23 medication. Any changes to medication use, for example dosing changes or new prescriptions,
24 will be recorded in the participant's medication log. Dietary supplement use will also be
25 recorded at baseline, 6 and 12 months. Assessment of functional status covering pain,
26 interference with daily activities and perceived health will be collected through interview using
27 questions from a validated scale.[39]
28
29
30
31
32
33

34 *Self-reported data*

35 *Gout flares*

36 Information on gout flares experienced by participants in the preceding 12 months will be
37 collected at baseline. This information covers frequency, duration, location, pain severity (0-
38 10 numerical rating scale) and treatment. During the 12-month supplementation period
39 participants will keep a diary to record all instances of gouty pain, again covering duration,
40 location, pain severity and treatment. A gout flare will be recorded if self-reported pain at rest
41 is >3.[40]
42
43
44
45
46
47
48

49 *Assessment of diet and physical activity levels*

50 Participants will complete a 4-day food diary using estimated household measures and record
51 physical activity in a diary over a 4-d period in the week preceding each laboratory visit.
52
53
54

55 *Compliance*

56 A daily calendar will be completed to record adherence to the intervention. Routine monthly
57 telephone contact and face-to-face contact when delivering the drinks will be used to encourage
58 compliance.
59
60

Retention

Participants may withdraw from the study at any time without giving any reason. Reasons for discontinuing the study will be recorded. Participants who decide to discontinue the intervention will be invited to return for follow-up visits to assess outcome measures.

Adverse events (AEs)

All AEs will be recorded and reported, where applicable, following Good Clinical Practice and Health Research Authority guidelines. Participants will be advised to report all serious or non-serious AEs to the research team; these data will be recorded. Additionally, the incidence of adverse events will be logged at laboratory visits and via telephone contact.

Data management

The collection and storage of data will adhere to the standard requirements of the EU General Data Protection Regulation 2016/679. Data will be entered onto electronic spreadsheets, which will be stored on a secure University server. All data will be treated confidentially and anonymised for evaluation. Hard copies of data and documents will be kept in a locked and secure cabinet for the duration of the study. Following completion of the study, data will be transferred to Sheffield Hallam University's Research Data Archive (SHURDA), where it will be kept for 10 years. Hard copies will be disposed of confidentially and electronic data deleted after this period of time.

Randomisation, allocation and blinding

All consenting participants will be block randomised (block size 4) in a 1:1 allocation to either a tart cherry juice group or a placebo cherry-flavoured drink group with stratification by sex and smoking status. Allocation sequence will be generated using a computer random number generator by an investigator not involved in participant enrolment and data collection (AL) and concealed from research personnel until the completion of the trial. The study coordinator (KL) who will be responsible for participant enrolment, distribution of intervention drinks and data collection will be blinded to treatment allocation until results have been analysed. Drinks will be provided to participants in identical bottles and labelled with participant identification number only to ensure that both study coordinator and participants are blinded to drink allocation throughout the study.

Sample size

The power calculation was based on the potential impact of tart cherry supplementation on the primary outcome measure. Using data on gout occurrence in UK patients, the chance of a

1
2
3 recurrence of at least one gout flare over a 12-month period is 11%.[41] It is predicted that
4 cherry juice treatment will reduce this recurrence to one quarter of the rate of the actual
5 recurrence (from 11% to 2.7%). Based on these data, it is estimated that 94 participants would
6 provide 95% power at a significance level of 0.05. A sample of 120 participants will allow for
7 an attrition rate of approximately 20%.
8
9
10
11

12 **Statistical analysis**

13 Continuous variables will be presented as mean and confidence intervals. Statistical
14 significance will be set at $p < 0.05$. Descriptive analysis of all baseline variables will be
15 conducted to compare the two groups. All analyses will be performed using intention-to-treat
16 analysis; all randomised participants will be included in the final analysis as far as data
17 collected will allow. Independent generalised mixed model analyses of variance will be
18 performed to test for changes in frequency of flares from baseline to 12 months between
19 treatments (cherry *versus* placebo); baseline, 6 months and 12 months times will be used for
20 secondary outcomes. Analysis will be performed using IBM SPSS Statistics for Windows
21 (New York, USA).
22
23
24
25
26
27
28
29

30 **Patient and public involvement**

31 Gout patients were not directly involved in development of the research question or study
32 design. We consulted with retired people from a local church group (Christ Church Fulwood,
33 Sheffield, England) as to their understanding of written participant information and
34 questionnaires. This group also provided feedback on the acceptability of the schedule of
35 visits, study measures and intervention.
36
37
38
39
40

41 **Ethics and dissemination**

42 The trial has been approved by Leeds West NHS Research Ethics Committee (18/SW/0262)
43 and the HRA and Health and Care Research Wales (HCRW). It is registered at
44 ClinicalTrials.gov (NCT03621215). Any protocol modifications will be sent for review by the
45 research ethics committee and will be amended at the trial registry. Participants will be sent a
46 summary of the trial findings when all data have been analysed. Dissemination of the study
47 findings of this study will be through publication in a leading peer-reviewed journal and
48 presentation at national and international conferences.
49
50
51
52
53
54

55 **Author affiliations**

56 ¹Food and Nutrition Group, Sheffield Business School, Sheffield Hallam University, Sheffield, UK

57 ²Corporate Information and Computing, University of Sheffield, Sheffield, UK
58
59
60

Acknowledgements

We acknowledge the input of Dr Tim Tait, Consultant Rheumatologist, United Lincolnshire Hospitals NHS Trust, Lincoln, England for his guidance about clinical aspects of the study protocol. We are grateful to Dr Caroline Mitchell and Dr Helen Twohig from the Academic Unit of Primary Medical Care, University of Sheffield for their helpful advice.

Contributors

AL and MEB designed the study and secured the funding. KL prepared study documents and coordinated the HRA and ethics applications. MEB and AL are joint principal investigators. KL is the study coordinator and co-investigator. KL drafted the manuscript for publication, with input from AL, JMR and MEB. JMR advised on the study design, power calculation and statistical analysis.

Funding

The sponsor of this research is Sheffield Hallam University, UK. This work is supported by the Cherry Marketing Institute (CMI), Michigan, US. CMI did not have any input into the design of the study or writing of this manuscript and will not play any role in the collection, analysis and interpretation of data. The protocol was initiated and designed by the investigators who have no personal financial relationships with CMI.

Patient recruitment to the study is supported by Yorkshire and Humber National Institute for Health Research CRN.

Competing interests

MEB and AL are the joint recipients of a research grant from the CMI, Michigan, US. None of the authors have any personal financial relationships with CMI.

Ethics approval

The study protocol (version 2.0, January 2019) was reviewed and approved by Yorkshire and The Humber Leeds West REC (Ref: 18/SW/0262).

Provenance and peer review

Not commissioned; externally peer reviewed.

Open Access

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

1
2
3
4
5
6
7
8 **Figure 1.** Participant flow through the study. PA; physical activity
9
10
11
12
13
14
15
16
17

18 REFERENCES

- 19 1 Hui M, Carr A, Cameron S, *et al.* The British Society for Rheumatology Guideline for
20 the Management of Gout. *Rheumatology* 2017;**56**:1–20.
21 doi:10.1093/rheumatology/kex156
22
- 23 2 Kuo C-F, Grainge MJ, Zhang W, *et al.* Global epidemiology of gout: prevalence,
24 incidence and risk factors. *Nat Rev Rheumatol* 2015;**11**:649–62.
25 doi:10.1038/nrrheum.2015.91
26
- 27 3 Kuo CF, Grainge MJ, Mallen C, *et al.* Rising burden of gout in the UK but continuing
28 suboptimal management: A nationwide population study. *Ann Rheum Dis*
29 2015;**74**:661–7. doi:10.1136/annrheumdis-2013-204463
30
- 31 4 Stack AG, Hanley A, Casserly LF, *et al.* Independent and conjoint associations of gout
32 and hyperuricaemia with total and cardiovascular mortality. *QJM* 2013;**106**:647–58.
33 doi:10.1093/qjmed/hct083
34
- 35 5 Kuo C-F, Grainge MJ, Mallen C, *et al.* Comorbidities in patients with gout prior to and
36 following diagnosis: case-control study. *Ann Rheum Dis* 2016;**75**:210–7.
37 doi:10.1136/annrheumdis-2014-206410
38
- 39 6 Roddy E, Doherty M. Epidemiology of gout. *Arthritis Res Ther* 2010;**12**:1–11.
40 doi:10.1186/ar3199
41
- 42 7 Dalbeth N, Merriman TR, Stamp LK. Gout. *Lancet* 2016;**388**:2039–52.
43 doi:10.1016/S0140-6736(16)00346-9
44
- 45 8 Roddy E. Revisiting the pathogenesis of podagra: Why does gout target the foot? *J*
46 *Foot Ankle Res* 2011;**4**:1–6. doi:10.1186/1757-1146-4-13
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 9 Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding
4 of the renal basis of hyperuricemia and the development of novel antihyperuricemic
5 therapeutics. *Arthritis Res Ther* 2006;**8**:1–9. doi:10.1186/ar1909
6
7
8
9
10 10 Abhishek A, Doherty M. Education and non-pharmacological approaches for gout.
11 *Rheumatology* 2018;**57**:51–8. doi:10.1093/rheumatology/kex421
12
13
14 11 Choi HK, Atkinson K, Karlson EW, *et al.* Alcohol intake and risk of incident gout in
15 men: A prospective study. *Lancet* 2004;**363**:1277–81. doi:10.1016/S0140-
16 6736(04)16000-5
17
18
19
20 12 Choi JW, Ford ES, Gao X, *et al.* Sugar-sweetened soft drinks, diet soft drinks, and
21 serum uric acid level: The third National Health and Nutrition Examination Survey.
22 *Arthritis Rheum* 2008;**59**:109–16. doi:10.1002/art.23245
23
24
25
26 13 Major TJ, Topless RK, Dalbeth N, *et al.* Evaluation of the diet wide contribution to
27 serum urate levels: meta-analysis of population based cohorts. *Br Med J Open*
28 2018;**363**:1–10. doi:10.1136/bmj.k3951
29
30
31
32 14 Wang M, Jiang X, Wu W, *et al.* A meta-analysis of alcohol consumption and the risk
33 of gout. *Clin Rheumatol* 2013;**32**:1641–8. doi:10.1007/s10067-013-2319-y
34
35
36 15 Wang DD, Sievenpiper JL, de Souza RJ, *et al.* The effects of fructose intake on serum
37 uric acid vary among controlled dietary trials. *J Nutr* 2012;**142**:916–23.
38 doi:10.3945/jn.111.151951
39
40
41
42 16 White SJ, Carran EL, Reynolds AN, *et al.* The effects of apples and apple juice on
43 acute plasma uric acid concentration: a randomized controlled trial. *Am J Clin Nutr*
44 2018;**107**:165–72. doi:10.1093/ajcn/nqx059
45
46
47
48 17 Blau LW. Cherry diet control for gout and arthritis. *Tex Rep Biol Med* 1950;**8**:309–11.
49
50
51 18 Bell PG, Gaze DC, Davison GW, *et al.* Montmorency tart cherry (*Prunus cerasus* L.)
52 concentrate lowers uric acid, independent of plasma cyanidin-3-O-glucosiderutinoside.
53 *J Funct Foods* 2014;**11**:82–90. doi:10.1016/j.jff.2014.09.004
54
55
56 19 Jacob RA, Spinozzi GM, Simon VA, *et al.* Consumption of cherries lowers plasma
57 urate in healthy women. *J Nutr* 2003;**133**:1826–9. doi:10.1093/jn/133.6.1826
58
59
60

- 1
2
3 20 Martin KR, Coles KM. Consumption of 100% tart cherry juice reduces serum urate in
4 overweight and obese adults. *Curr Dev Nutr* 2019;**3**:1–9. doi:10.1093/cdn/nzz011
5
6
7 21 Zhang Y, Neogi T, Chen C, *et al.* Cherry consumption and decreased risk of recurrent
8 gout attacks. *Arthritis Rheum* 2012;**64**:4004–11. doi:10.1002/art.34677
9
10
11 22 Schlesinger N, Rabinowitz R, Schlesinger M. Pilot studies of cherry juice concentrate
12 for gout flare prophylaxis. *J Arthritis* 2012;**01**:1–5. doi:10.4172/2167-7921.1000101
13
14
15 23 Singh JA, Green C, Morgan S, *et al.* A randomized internet-based pilot feasibility and
16 planning study of cherry extract and diet modification in gout. *J Clin*
17 *Rheumatol*;:Published Online First: 23 January 2019.
18 doi:10.1097/RHU.0000000000001004
19
20
21
22
23 24 Kelley DS, Rasooly R, Jacob RA, *et al.* Consumption of Bing sweet cherries lowers
24 circulating concentrations of inflammation markers in healthy men and women. *J Nutr*
25 2006;**136**:981–6. doi:10.1093/jn/136.4.981
26
27
28
29 25 Kelley DS, Adkins Y, Reddy A, *et al.* Sweet Bing cherries lower circulating
30 concentrations of markers for chronic inflammatory diseases in healthy humans. *J Nutr*
31 2013;**143**:340–4. doi:10.3945/jn.112.171371.the
32
33
34
35 26 Chai S, Davis K, Zhang Z, *et al.* Effects of tart cherry juice on biomarkers of
36 inflammation and oxidative stress in older adults. *Nutrients* 2019;**11**:228.
37 doi:10.3390/nu11020228
38
39
40
41 27 Kuehl KS, Elliot DL, Sleigh AE, *et al.* Efficacy of tart cherry juice to reduce
42 inflammation biomarkers among women with inflammatory osteoarthritis (OA). *J*
43 *Food Stud* 2012;**1**:14–25. doi:10.5296/jfs.v1i1.1927
44
45
46
47 28 Schumacher HR, Pullman-Mooar S, Gupta SR, *et al.* Randomized double-blind
48 crossover study of the efficacy of a tart cherry juice blend in treatment of osteoarthritis
49 (OA) of the knee. *Osteoarthr Cartil* 2013;**21**:1035–41. doi:10.1016/j.joca.2013.05.009
50
51
52
53 29 NICE. Clinical Knowledge Summary: Gout.
54 2018.<https://cks.nice.org.uk/gout#!scenario:1> (accessed 5 Sep 2019).
55
56
57
58 30 Richette P, Doherty M, Pascual E, *et al.* 2016 updated EULAR evidence-based
59 recommendations for the management of gout. *Ann Rheum Dis* 2017;**76**:29–42.
60

- 1
2
3 doi:10.1136/annrheumdis-2016-209707
4
5
6 31 Arthritis Research UK. Gout. 2016.[https://www.versusarthritis.org/about-](https://www.versusarthritis.org/about-arthritis/conditions/gout/)
7 arthritis/conditions/gout/ (accessed 6 Jun 2019).
8
9
10 32 Mayo Clinic. Gout: Diagnosis and treatment.
11 2019.[https://www.mayoclinic.org/diseases-conditions/gout/diagnosis-treatment/drc-](https://www.mayoclinic.org/diseases-conditions/gout/diagnosis-treatment/drc-20372903)
12 20372903 (accessed 4 Jun 2019).
13
14
15
16 33 UK Gout Society. All about gout and diet.
17 <http://www.ukgoutsociety.org/PDFs/goutsociety-allaboutgoutanddiet-0917.pdf>
18 (accessed 9 Feb 2019).
19
20
21
22 34 U.S. Food and Drug Administration. List of firms receiving warning letters regarding
23 cherry and other fruit-based products with disease claims in labeling.
24 2005.[http://wayback.archive-](http://wayback.archive-it.org/7993/20170406024549/https://www.fda.gov/Food/ComplianceEnforcement/War)
25 it.org/7993/20170406024549/<https://www.fda.gov/Food/ComplianceEnforcement/War>
26 ningLetters/ucm081724.htm (accessed 5 May 2019).
27
28
29
30
31 35 Duyck SD, Petrie KJ, Dalbeth N. “You don’t have to be a drinker to get gout, but it
32 helps”: a content analysis of the depiction of gout in popular newspapers. *Arthritis*
33 *Care Res* 2016;**68**:1721–5. doi:10.1002/acr.22879
34
35
36
37 36 NHS Choices. Cherry juice touted as treatment for gout.
38 2014.[https://www.nhs.uk/news/food-and-diet/cherry-juice-touted-as-treatment-for-](https://www.nhs.uk/news/food-and-diet/cherry-juice-touted-as-treatment-for-gout/)
39 gout/ (accessed 17 Jun 2018).
40
41
42
43 37 Chan A, Tetzlaff JM, Altman DG, *et al.* SPIRIT 2013 statement: Defining standard
44 protocol items for clinical trials. *Ann Intern Med* 2013;**158**:200–7.
45
46
47
48 38 Caliceti C, Calabria D, Roda A, *et al.* Fructose intake, serum uric acid, and
49 cardiometabolic disorders: A critical review. *Nutrients* 2017;**9**:395.
50 doi:10.3390/nu9040395
51
52
53
54 39 Álvarez-Hernández E, Peláez-Ballestas I, Vázquez-Mellado J, *et al.* Validation of the
55 Health Assessment Questionnaire Disability Index in patients with gout. *Arthritis*
56 *Rheum* 2008;**59**:665–9. doi:10.1002/art.23575
57
58
59
60 40 Dalbeth N, Ames R, Gamble GD, *et al.* Effects of skim milk powder enriched with

glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. *Ann Rheum Dis* 2012;**71**:929–34.

doi:10.1136/annrheumdis-2011-200156

- 41 Rothenbacher D, Primatesta P, Ferreira A, *et al.* Frequency and risk factors of gout flares in a large population-based cohort of incident gout. *Rheumatology* 2011;**50**:973–81. doi:10.1093/rheumatology/keq363

For peer review only




Figure 1. Participant flow through the study. PA; physical activity

209x104mm (300 x 300 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	n/a
Protocol version	#3	Date and version identifier	11
Funding	#4	Sources and types of financial, material, and other support	10-11
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1, 10

1	Roles and	#5b	Name and contact information for the trial sponsor	10
2	responsibilities:			
3	sponsor contact			
4	information			
5				
6				
7				
8	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	10-11
9	responsibilities:		collection, management, analysis, and interpretation of	
10	sponsor and funder		data; writing of the report; and the decision to submit the	
11			report for publication, including whether they will have	
12			ultimate authority over any of these activities	
13				
14				
15				
16	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	n/a
17	responsibilities:		centre, steering committee, endpoint adjudication	
18	committees		committee, data management team, and other individuals	
19			or groups overseeing the trial, if applicable (see Item 21a	
20			for data monitoring committee)	
21				
22				
23				
24	Introduction			
25				
26				
27	Background and	#6a	Description of research question and justification for	3
28	rationale		undertaking the trial, including summary of relevant	
29			studies (published and unpublished) examining benefits	
30			and harms for each intervention	
31				
32				
33				
34	Background and	#6b	Explanation for choice of comparators	7
35	rationale: choice of			
36	comparators			
37				
38				
39	Objectives	#7	Specific objectives or hypotheses	4-5
40				
41	Trial design	#8	Description of trial design including type of trial (eg,	5
42			parallel group, crossover, factorial, single group),	
43			allocation ratio, and framework (eg, superiority,	
44			equivalence, non-inferiority, exploratory)	
45				
46				
47				
48	Methods:			
49	Participants,			
50	interventions, and			
51	outcomes			
52				
53				
54				
55	Study setting	#9	Description of study settings (eg, community clinic,	5
56			academic hospital) and list of countries where data will be	
57			collected. Reference to where list of study sites can be	
58				
59				
60				

obtained

1			
2			
3	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
4			
5			
6			
7			
8			
9	Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
10			
11			
12			
13			
14	Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)
15			
16			
17			
18			
19			
20			
21	Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)
22			
23			
24			
25			
26			
27	Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
28			
29			
30			
31	Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42	Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
43			
44			
45			
46			
47			
48			
49	Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
50			
51			
52			
53			
54			
55	Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size
56			
57			
58			
59			
60			

1 **Methods:**

2 **Assignment of**
3 **interventions (for**
4 **controlled trials)**
5
6

7			
8	Allocation: sequence	#16a	Method of generating the allocation sequence (eg, 9
9	generation		computer-generated random numbers), and list of any
10			factors for stratification. To reduce predictability of a
11			random sequence, details of any planned restriction (eg,
12			blocking) should be provided in a separate document that
13			is unavailable to those who enrol participants or assign
14			interventions
15			
16			
17			
18			
19	Allocation	#16b	Mechanism of implementing the allocation sequence (eg, 9
20	concealment		central telephone; sequentially numbered, opaque, sealed
21	mechanism		envelopes), describing any steps to conceal the sequence
22			until interventions are assigned
23			
24			
25			
26	Allocation:	#16c	Who will generate the allocation sequence, who will enrol 9
27	implementation		participants, and who will assign participants to
28			interventions
29			
30			
31	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, 9
32			trial participants, care providers, outcome assessors, data
33			analysts), and how
34			
35			
36			
37	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is
38	emergency unblinding		permissible, and procedure for revealing a participant's
39			allocated intervention during the trial
40			
41			

42 **Methods: Data**
43 **collection,**
44 **management, and**
45 **analysis**
46
47

48			
49	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, 7-8
50			and other trial data, including any related processes to
51			promote data quality (eg, duplicate measurements,
52			training of assessors) and a description of study
53			instruments (eg, questionnaires, laboratory tests) along
54			with their reliability and validity, if known. Reference to
55			where data collection forms can be found, if not in the
56			
57			
58			
59			
60			

protocol

1			
2			
3	Data collection plan:	#18b	Plans to promote participant retention and complete
4	retention		follow-up, including list of any outcome data to be
5			collected for participants who discontinue or deviate from
6			intervention protocols
7			
8			
9	Data management	#19	Plans for data entry, coding, security, and storage,
10			including any related processes to promote data quality
11			(eg, double data entry; range checks for data values).
12			Reference to where details of data management
13			procedures can be found, if not in the protocol
14			
15			
16			
17			
18	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary
19			outcomes. Reference to where other details of the
20			statistical analysis plan can be found, if not in the protocol
21			
22			
23	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and
24	analyses		adjusted analyses)
25			
26			
27	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-
28	population and		adherence (eg, as randomised analysis), and any
29	missing data		statistical methods to handle missing data (eg, multiple
30			imputation)
31			
32			
33	Methods: Monitoring		
34			
35			
36	Data monitoring:	#21a	Composition of data monitoring committee (DMC);
37	formal committee		summary of its role and reporting structure; statement of
38			whether it is independent from the sponsor and competing
39			interests; and reference to where further details about its
40			charter can be found, if not in the protocol. Alternatively,
41			an explanation of why a DMC is not needed
42			
43			
44			
45			
46	Data monitoring:	#21b	Description of any interim analyses and stopping
47	interim analysis		guidelines, including who will have access to these interim
48			results and make the final decision to terminate the trial
49			
50			
51	Harms	#22	Plans for collecting, assessing, reporting, and managing
52			solicited and spontaneously reported adverse events and
53			other unintended effects of trial interventions or trial
54			conduct
55			
56			
57			
58	Auditing	#23	Frequency and procedures for auditing trial conduct, if
59			
60			

any, and whether the process will be independent from investigators and the sponsor

Ethics and dissemination

1				
2				
3				
4	Ethics and			
5	dissemination			
6				
7				
8	Research ethics	#24	Plans for seeking research ethics committee / institutional	10
9	approval		review board (REC / IRB) approval	
10				
11	Protocol amendments	#25	Plans for communicating important protocol modifications	10
12			(eg, changes to eligibility criteria, outcomes, analyses) to	
13			relevant parties (eg, investigators, REC / IRBs, trial	
14			participants, trial registries, journals, regulators)	
15				
16				
17				
18	Consent or assent	#26a	Who will obtain informed consent or assent from potential	6
19			trial participants or authorised surrogates, and how (see	
20			Item 32)	
21				
22				
23				
24	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
25	ancillary studies		participant data and biological specimens in ancillary	
26			studies, if applicable	
27				
28				
29	Confidentiality	#27	How personal information about potential and enrolled	8-9
30			participants will be collected, shared, and maintained in	
31			order to protect confidentiality before, during, and after the	
32			trial	
33				
34				
35				
36	Declaration of	#28	Financial and other competing interests for principal	11
37	interests		investigators for the overall trial and each study site	
38				
39				
40	Data access	#29	Statement of who will have access to the final trial dataset,	11
41			and disclosure of contractual agreements that limit such	
42			access for investigators	
43				
44				
45	Ancillary and post trial	#30	Provisions, if any, for ancillary and post-trial care, and for	n/a
46	care		compensation to those who suffer harm from trial	
47			participation	
48				
49				
50	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	10
51	trial results		results to participants, healthcare professionals, the public,	
52			and other relevant groups (eg, via publication, reporting in	
53			results databases, or other data sharing arrangements),	
54			including any publication restrictions	
55				
56				
57				
58				
59	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of	n/a
60				

1 authorship professional writers
 2
 3 Dissemination policy: [#31c](#) Plans, if any, for granting public access to the full protocol, n/a
 4 reproducible research participant-level dataset, and statistical code
 5

6 **Appendices**

8 Informed consent [#32](#) Model consent form and other related documentation n/a
 9 materials given to participants and authorised surrogates
 10
 11

12 Biological specimens [#33](#) Plans for collection, laboratory evaluation, and storage of n/a
 13 biological specimens for genetic or molecular analysis in
 14 the current trial and for future use in ancillary studies, if
 15 applicable
 16
 17
 18

19 None The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution
 20 License CC-BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a
 21 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60